Session Chair Profile

M.D., Ph.D., Professor, Laboratory Medicine, UCSF

Biography
Charles Chiu, M.D./Ph.D. is a Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory, He is a board-certified consulting infectious diseases physician at UCSF, and practices in both infectious diseases and clinical microbiology. Dr. Chiu obtained an MD and PhD in biophysics from UCLA and subsequently completed an internal medicine residency, infectious diseases fellowship, and postdoctoral research at UCSF. He heads a translational research laboratory engaged in clinical next-generation sequencing assay development for diagnosis of infectious diseases, pathogen discovery, bioinformatics software development, nanopore sequencing, and characterization of emerging infections (Lyme disease, enterovirus D68, and Zika virus). His work is supported by research grants from the NIH, Abbott Laboratories, Bay Area Lyme Disease Foundation, Global Lyme Alliance, USAID PREDICT program, UC Center for Accelerated Innovation, Sandler / Bowes Foundation, and California Initiative to Advance Precision Medicine. Dr. Chiu has authored more than 50 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Therabio, Karius, and Rubicon Genomics.


 Session Abstract – PMWC 2022 Silicon Valley


Large-scale genomic sequencing efforts are of ever-increasing importance especially in the context of early pathogen detection, disease outbreak prevention, and establishing a predictive and efficient public health response. Rapid generation and access to genomic sequence data for viruses and other pathogens, which could cause a pandemic or serious outbreak, enables the tracking of variants and emerging pathogens (e.g., SARS-CoV-2, influenza, enterovirus D68, antibiotic-resistant bacteria, etc.), and thus the expedient development of diagnostics, vaccines, and therapeutics essential to supporting public health responses. This very important subject will be the focus of this session.